News | September 12, 2024
Merck launches single-use reactor to accelerate ADC manufacturing
Increases efficiency by 70% compared to stainless steel or glass manufacturing methods
Increases efficiency by 70% compared to stainless steel or glass manufacturing methods
Third Phase 3 trial in third type of lymphoma to show improvement in overall survival with an ADCETRIS-containing regimen
Merck shared updates on the company’s oncology pipeline and focused R&D approach
The HD21 study adds to the body of evidence supporting ADCETRIS as a backbone agent in the treatment of specific lymphomas
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS
The company intends to respond to the two minor observations within the stipulated time
IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate
The commissioning of the facility represents the culmination of a £45m investment to address rapidly growing demand for ADC manufacturing, supported by a £2.4m Scottish Enterprise grant
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Subscribe To Our Newsletter & Stay Updated
